Teriparatide is an FDA-approved anabolic bone-building agent consisting of the first 34 amino acids of parathyroid hormone. Unlike antiresorptive osteoporosis drugs that slow bone loss, teriparatide actively stimulates new bone formation. The key to its mechanism is intermittent exposure: while continuous PTH causes bone resorption, daily injections stimulate osteoblasts more than osteoclasts, resulting in net bone formation. Clinical trials show 8% spine bone density increases and 65% reduction in vertebral fractures.

Mechanism of Action

Teriparatide binds to PTH type 1 receptors (G-protein coupled receptors) on osteoblasts, osteocytes, and renal tubular cells. This activates PKA and PKC signaling pathways that promote osteoblast activity. The intermittent daily dosing creates an 'anabolic window' where bone formation exceeds resorption. Teriparatide upregulates IGF-1 and FGF2 expression, stimulates bone formation on trabecular and cortical surfaces, and increases bone mineral density through preferential osteoblast stimulation.

Safety Profile

Safety Profile: Teriparatide

Common Side Effects

• Nausea (most common, affecting ~10–15% of patients)
• Headache and dizziness
• Leg cramps and arthralgia
• Injection site reactions: pain, erythema, and swelling
• Orthostatic hypotension (particularly within 4 hours of first dose)
• Mild transient hypercalcemia
• Rhinitis

Serious Adverse Effects

• Osteosarcoma risk: Black box warning based on rat studies showing dose- and duration-dependent osteosarcoma; risk in humans appears very low but led to the original 2-year treatment limit (now extended based on reassuring surveillance data)
• Hypercalcemia: Clinically significant in ~11% of patients; usually transient post-dose peaks
• Hyperuricemia and gout exacerbation
• Orthostatic hypotension severe enough to cause syncope (rare)
• Rare cases of urolithiasis aggravation due to hypercalciuria

Contraindications

• Osteosarcoma risk factors: Paget's disease, unexplained alkaline phosphatase elevation, prior radiation therapy involving the skeleton, open epiphyses (children/adolescents), pre-existing hypercalcemia
• Bone metastases or skeletal malignancies
• Metabolic bone disease other than osteoporosis (e.g., hyperparathyroidism)
• Pre-existing hypercalcemia
• Pregnancy (category C; teratogenic in animal studies)

Drug Interactions

• Digoxin: Hypercalcemia from teriparatide may potentiate digoxin toxicity
• Calcium and vitamin D supplements: Necessary adjuncts but may contribute to hypercalcemia; monitor serum calcium
• Bisphosphonates: Sequential therapy (teriparatide first, then bisphosphonate) is more effective than concurrent use; combination may blunt anabolic effect
• Thiazide diuretics: May exacerbate hypercalcemia
• Glucocorticoids: Teriparatide is particularly effective in glucocorticoid-induced osteoporosis

Population-Specific Considerations

• Treatment duration: Traditionally limited to 2 years due to osteosarcoma concern; followed by antiresorptive therapy to maintain gains
• Postmenopausal women: Primary indication; increases BMD and reduces vertebral and non-vertebral fractures
• Men with osteoporosis: FDA-approved; significant fracture reduction demonstrated
• Glucocorticoid-induced osteoporosis: Superior to bisphosphonates in this population
• Self-injection: Requires patient/caregiver training; pen device is user-friendly
• Monitoring: Serum calcium at 1 month and periodically; serum uric acid if gout history

Pharmacokinetic Profile